» Articles » PMID: 28148894

Predictive Value of Hematological Markers of Systemic Inflammation for Managing Cervical Cancer

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Feb 3
PMID 28148894
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) are markers of systemic inflammation with prognostic significance for cancers. The aim of the study was to investigate the predictive significance of pretreatment values of NLR, PLR, and RDW in cervical cancer. We retrospectively analyzed 515 patients with cancer. Median values of NLR and PLR were higher in patients with cancer compared with controls and were consistently elevated during tumor progression, while the RDW was uninformative. Increased NLR was associated with lymph node (LN) metastasis and depth of stromal infiltration, and increased PLR correlated only with LN metastasis. The pretreatment NLR or PLR value was a significant predictor of LN metastasis, which enhanced when NLR and PLR values were combined. Further, NLR and PLR were as effective as squamous cell carcinoma antigen (SCC-Ag) for predicting distant tumor metastasis. However, no prognostic significance of NLR or PLR was found in the patients with early cancer stages. Our study suggested that pretreatment values of NLR and PLR might be helpful to predict the presence of distant and LN metastasis in patients with cervical carcinoma, but not adequate prognostic factors for early stage patients.

Citing Articles

Comprehensive Evaluation of Inflammatory Biomarkers in Cervical Cancer Treated with Chemoradiotherapy.

Koca T, Gocen Vardar N, Aksoy R, Korcum A Curr Oncol. 2025; 32(1).

PMID: 39851955 PMC: 11763994. DOI: 10.3390/curroncol32010039.


The Prognostic Value of the Systemic Immune-Inflammation Index (SII) and Red Cell Distribution Width (RDW) in Patients with Cervical Cancer Treated Using Radiotherapy.

Staniewska E, Grudzien K, Stankiewicz M, Raczek-Zwierzycka K, Rembak-Szynkiewicz J, Nowicka Z Cancers (Basel). 2024; 16(8).

PMID: 38672624 PMC: 11049631. DOI: 10.3390/cancers16081542.


Nomograms for predicting prognostic value of combined neutrophil-to-lymphocyte ratio and SCC-Ag in locally advanced cervical cancer.

Jin L, Cao F, Zhang Y, Dang Y, Wang F Transl Cancer Res. 2024; 13(3):1323-1335.

PMID: 38617514 PMC: 11009798. DOI: 10.21037/tcr-23-1501.


Pre-treatment inflammatory and immune system parameters predicting cervical cancer metastasis.

Avisha M, Pelupessy N, Rahman A, Rauf S, Rakhmah N, Hamid F Turk J Obstet Gynecol. 2023; 20(4):285-292.

PMID: 38073222 PMC: 10711526. DOI: 10.4274/tjod.galenos.2023.80912.


A Nomogram Incorporating Neutrophil-to-Lymphocyte Ratio and Squamous Cell Carcinoma Antigen Predicts the Prognosis of Oral Cancers.

Tsai Y, Lai C, Chang G, Hsu C, Tsai M, Liao C Cancers (Basel). 2023; 15(9).

PMID: 37173956 PMC: 10177202. DOI: 10.3390/cancers15092492.


References
1.
Shen G, Zhou H, Jia Z, Deng H . Diagnostic performance of diffusion-weighted MRI for detection of pelvic metastatic lymph nodes in patients with cervical cancer: a systematic review and meta-analysis. Br J Radiol. 2015; 88(1052):20150063. DOI: 10.1259/bjr.20150063. View

2.
Jia J, Zheng X, Chen Y, Wang L, Lin L, Ye X . Stage-dependent changes of preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in colorectal cancer. Tumour Biol. 2015; 36(12):9319-25. DOI: 10.1007/s13277-015-3667-9. View

3.
Yesil A, Senates E, Bayoglu I, Erdem E, Demirtunc R, Ovunc A . Red cell distribution width: a novel marker of activity in inflammatory bowel disease. Gut Liver. 2011; 5(4):460-7. PMC: 3240789. DOI: 10.5009/gnl.2011.5.4.460. View

4.
Lee Y, Choi C, Kim H, Kim T, Lee J, Lee J . Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res. 2012; 32(4):1555-61. View

5.
Duk J, Groenier K, de Bruijn H, Hollema H, ten Hoor K, van der Zee A . Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol. 1996; 14(1):111-8. DOI: 10.1200/JCO.1996.14.1.111. View